Skip to content

Author

Valentino Dragonetti

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel.

BACKGROUND The management of metastatic castration-resistant prostate cancer (mCRPC) after progression on androgen receptor pathway inhibitors (ARPI) and docetaxel presents a critical therapeutic choice between cabazitaxel and [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT). This review provides a comprehensive analy...

F. Mattana, E. Palesandro, Valentino Dragonetti et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.